Investigation of molecular and cellular determinants of Immune Related Adverse Events following treatment with Immune Checkpoint Inhibitors

免疫检查点抑制剂治疗后免疫相关不良事件的分子和细胞决定因素的研究

• 批准号: nhmrc : 1151082
• 金额: $ 8.55万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigation-molecular-cellular-checkpoint-inhibitors/1321285
• 关键词: Investigation; molecular; cellular; determinants; Immune

Novel immune-based treatments for advanced, incurable, cancer have significantly improved patient survival. Although these treatments have proven highly effective, they are associated with the unpredictable development of severe and sometimes life-threatening autoimmune disease. We aim to discover ways to predict and potentially prevent these complications by identifying genetic risk factors and markers in blood samples. If successful, this will be a ground breaking advance in cancer care.

针对晚期、无法治愈的癌症的新型免疫疗法显着提高了患者的生存率。尽管这些治疗已被证明非常有效，但它们与严重且有时危及生命的自身免疫性疾病的不可预测的发展有关。我们的目标是通过识别血液样本中的遗传风险因素和标记物来发现预测和潜在预防这些并发症的方法。如果成功，这将是癌症治疗领域的突破性进展。